You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Perflubron - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for perflubron and what is the scope of freedom to operate?

Perflubron is the generic ingredient in one branded drug marketed by Alliance Pharm and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for perflubron
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 96
Clinical Trials: 4
Patent Applications: 6,340
DailyMed Link:perflubron at DailyMed
Recent Clinical Trials for perflubron

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
SolAeroMed Inc.Phase 2
ADAGP Charitable Foundation dba Auto Dealers CARing for Kids FoundationPhase 1
Children's Hospital of PhiladelphiaPhase 1

See all perflubron clinical trials

US Patents and Regulatory Information for perflubron

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alliance Pharm IMAGENT perflubron LIQUID;ORAL 020091-001 Aug 13, 1993 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Perflubron Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Perflubron

Introduction

Perflubron, a perfluorocarbon, has been gaining significant attention in the medical field, particularly for its use in total liquid ventilation (TLV) and partial liquid ventilation. This article delves into the market dynamics and financial trajectory of perflubron, highlighting its current status, future projections, and key factors influencing its market.

Current Market Status

The global perflubron market is experiencing a period of significant growth. Market research indicates that the market is expected to expand substantially from 2023 to 2031, driven by the increasing demand for advanced respiratory care solutions[1][4].

Market Drivers

Several factors are driving the growth of the perflubron market:

Advancements in Medical Technology

The development of advanced medical technologies, such as electrical impedance tomography and fluoroscopy, has enhanced the safety and efficacy of TLV using perflubron. These technologies allow for real-time monitoring and better management of lung recruitment and air evacuation, which are critical during the transition to TLV[2].

Increasing Prevalence of Respiratory Disorders

The rising incidence of respiratory distress, particularly in neonatal and critical care settings, is a significant driver. Perflubron's effectiveness in managing surfactant deficiency and other respiratory conditions has made it a valuable asset in intensive care units[2][3].

Clinical Trials and Research

Ongoing clinical trials and research studies are providing valuable insights into the use of perflubron. These studies help in refining the protocols for TLV and partial liquid ventilation, which in turn, boost market confidence and adoption[2][3].

Market Segmentation

The perflubron market can be segmented based on several criteria:

Application

  • Total Liquid Ventilation (TLV): Primarily used in neonatal care for managing respiratory distress.
  • Partial Liquid Ventilation (PLV): Used in adult critical care for patients with severe respiratory failure[2][3].

Geography

The market is analyzed across various regions, with significant growth expected in regions with advanced healthcare infrastructure and high demand for innovative respiratory care solutions[4].

Financial Trajectory

The financial outlook for the perflubron market is promising:

Market Size and Growth

The market is projected to experience substantial growth, with significant expansion anticipated from 2023 to 2031. This growth is driven by increasing demand, technological advancements, and favorable clinical outcomes[1][4].

Revenue Projections

The revenue generated from the perflubron market is expected to rise significantly over the forecast period. This increase is attributed to the higher adoption rates of TLV and PLV in both developed and developing countries[4].

Key Players and Competitive Landscape

The competitive landscape of the perflubron market includes several key players involved in the production, distribution, and research of perflubron. These companies are investing heavily in research and development to improve the efficacy and safety of perflubron-based treatments[4].

Regulatory Environment

Regulatory approvals and guidelines play a crucial role in the market dynamics of perflubron. Stringent regulatory frameworks ensure the safety and efficacy of perflubron, which in turn, influence market growth. Compliance with these regulations is essential for market players to maintain their competitive edge[3].

Challenges and Opportunities

While the market for perflubron is growing, there are several challenges and opportunities to consider:

Challenges

  • High Cost: The high cost of perflubron and the associated technologies can be a barrier to widespread adoption.
  • Safety Concerns: The transition phase to TLV requires careful management to avoid ventilator-induced lung injury, which can be a challenge in clinical settings[2].

Opportunities

  • Expanding Applications: Research into new applications of perflubron, such as in preclinical models for other conditions, could expand its market potential.
  • Technological Advancements: Continued advancements in monitoring and management technologies can enhance the safety and efficacy of perflubron-based treatments[2][5].

Distribution and Elimination

Understanding the distribution and elimination of perflubron is crucial for its clinical use:

Pulmonary Distribution

Perflubron tends to distribute and remain for longer periods in the dependent regions of the lung compared to the non-dependent regions. This distribution pattern is critical for effective ventilation and lung protection[3].

Systemic Elimination

Perflubron is eliminated primarily through evaporative loss from the airways, with a maximum rate of 9.4 mL/h. It also results in low but measurable blood concentrations, which decrease gradually after the cessation of partial liquid ventilation[3].

Conclusion

The market for perflubron is poised for significant growth driven by technological advancements, increasing demand for advanced respiratory care, and favorable clinical outcomes. While there are challenges to be addressed, the opportunities in this market are substantial, making perflubron a promising area for investment and research.

Key Takeaways

  • Market Growth: The perflubron market is expected to expand significantly from 2023 to 2031.
  • Technological Advancements: Real-time monitoring technologies like electrical impedance tomography and fluoroscopy are enhancing the safety and efficacy of TLV.
  • Clinical Applications: Perflubron is primarily used in TLV for neonatal care and PLV for adult critical care.
  • Distribution and Elimination: Perflubron distributes more in dependent lung regions and is eliminated mainly through evaporative loss from the airways.
  • Regulatory Environment: Compliance with regulatory frameworks is crucial for market growth.

FAQs

Q: What is the primary use of perflubron in medical settings? A: Perflubron is primarily used in total liquid ventilation (TLV) for neonatal care and partial liquid ventilation (PLV) for adult critical care.

Q: How does perflubron distribute within the lungs? A: Perflubron tends to distribute and remain for longer periods in the dependent regions of the lung compared to the non-dependent regions[3].

Q: What is the rate of elimination of perflubron from the body? A: Perflubron is eliminated primarily through evaporative loss from the airways at a maximum rate of 9.4 mL/h[3].

Q: What technologies are used to monitor the transition to TLV using perflubron? A: Electrical impedance tomography and fluoroscopy are used to monitor the transition to TLV, ensuring better lung recruitment and air evacuation[2].

Q: What are the potential challenges in the use of perflubron? A: High cost, safety concerns during the transition phase, and the need for careful management to avoid ventilator-induced lung injury are potential challenges[2].

Sources

  1. Market Research Intellect - Perflubron Market Size, Scope And Forecast Report
  2. Frontiers in Physiology - Perflubron Distribution During Transition From Gas to Total Liquid Ventilation
  3. PubMed - The pulmonary and systemic distribution and elimination of perflubron
  4. River Country News Channel Nebraska - Perflubron Market Growth 2024-2031
  5. Science - Translating insights into therapies for Long Covid

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.